Palatin Technologies Inc
Research Palatin Technologies Inc (PTN) on Bullrun: market cap USD 15.19M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerPTN
- ExchangeAMEX
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 15.19M
- Financial periodQ1 2026
- RevenueUSD 3.92M
- Net income-USD 1.43M
- Free cash flow-USD 4.46M
Valuation Snapshot
latest market cap is USD 15.19M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 0 | -USD 17.31M | -USD 21.31M | n/a | -32.15 | USD 2.56M | USD 163.78K | -USD 4.78M |
| FY2024 | USD 4.49M | -USD 29.74M | -USD 31.50M | 97.8% | -101.16 | USD 9.53M | USD 590.34K | -USD 111.50K |
| FY2023 | USD 4.85M | -USD 24.04M | -USD 29.71M | 91.4% | -110.5 | USD 10.98M | USD 1.05M | -USD 1.98M |
| FY2022 | USD 1.47M | -USD 36.20M | -USD 30.18M | 85.2% | -189.5 | USD 29.94M | USD 1.15M | USD 16.27M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-12 | USD 15.19M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 14.30M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 26.04M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 54.67M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 26.51M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 118.19M | n/a | n/a | n/a |
About Palatin Technologies Inc
Palatin Technologies, Inc., a biopharmaceutical company, develops first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system in the United States. It is developing oral small molecule PL7737 agonist in preclinical studies; long-acting peptide MC4R agonists; and Bremelanotide co-administration with Tirzepatide to treat obesity completed Phase 2 clinical trial; completed a phase 2 of diabetic nephropathy It also provides pl9643 for dry eye disease;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Palatin Technologies Inc's market cap?
Palatin Technologies Inc's market capitalization is USD 15.19M.
What does Palatin Technologies Inc do?
Palatin Technologies, Inc., a biopharmaceutical company, develops first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system in the United States. It is developing oral small molecule PL7737 agonist in preclinical studies; long-acting peptide MC4R agonists; and Bremelanotide co-administration with Tirzepatide to treat obesity completed Phase 2 clinical trial; completed a phase 2 of diabetic nephropathy It also provides pl9643 for dry eye disease; and oral PL8177 for inflammatory bowel diseases.